Hemophilia A

  • Mohammad Saeed Gholami
  • Mohsen Valikhani
  • Akbar Dorgalaleh
  • Sayed Hamid Mousavi
  • Behnaz PezeshkpoorEmail author


Hemophilia A is an inherited X-linked recessive bleeding disorder that accounts for about 80% of cases of hemophilia, occurs in ~5 to ~20 per 100,000 male births, and is caused by a defect or deficiency in coagulation factor VIII (FVIII). Hemophilia A is due to different mutations in F8 gene; among them, intron 22 inversion, which leads to severe hemophilia A, is the most common. Patients with hemophilia A present different complications; among them abnormal bleeding in joints, and soft tissue is the most common. Different therapeutic choices are available for the patients including fresh frozen plasma (FFP), cryoprecipitate, plasma-derived FVIII concentrate, and various recombinant FVIII (rFVIII) concentrates. The only curative choice is gene therapy that can lead to lifelong eliminating of the disorder. With current therapeutic choices and supportive care, quality of life in patients with hemophilia A is significantly improved.


Hemophilia A Genetic diseases X-linked Factor VIII deficiency Gene therapy, Bleeding 



We appreciate Professor Edward Tuddenham for his valuable comments that significantly improved the quality of this chapter.


  1. 1.
    Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, et al. Characterization of the human factor VIII gene. Nature. 1984;312:326–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Bell B, Canty D, Audet M. Hemophilia: an updated review. Pediatrics in review. Am Acad Pediatr. 1995;16(8):290–8.CrossRefGoogle Scholar
  3. 3.
    Anwarul M, Yakub C. A review on hemophilia in children. Bangladesh J Child Health. 2013;37:27–40.Google Scholar
  4. 4.
    Madhok R, York J, Sturrock RD. Haemophilic arthritis. Ann Rheum Dis. 1991;50(8):588.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Luck Jr JV, Silva M, Rodriguez-Merchan CE, Ghalambor N, Zahiri CA, Finn RS. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004;12(4):234–45.CrossRefGoogle Scholar
  6. 6.
    Moser KA. Chromogenic factor VIII activity assay. Am J Hematol. 2014;89(7):781–4.PubMedCrossRefGoogle Scholar
  7. 7.
    White G, Rosendaal F, Aledort L, Lusher J, Rothschild C, Ingerslev J. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Srivastava A, Brewer A, Mauser-Bunschoten E, Key N, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1). Scholar
  9. 9.
    Bowen D. Haemophilia A and haemophilia B: molecular insights. J Clin Pathol. 2002;55(2):127.CrossRefGoogle Scholar
  10. 10.
    Keeney S, Mitchell M, Goodeve A. The molecular analysis of haemophilia A: a guideline from the UK haemophilia centre doctors’ organization haemophilia genetics laboratory network. Haemophilia. 2005;11(4):387–97.PubMedCrossRefGoogle Scholar
  11. 11.
    Bihoreau N, Pin S, Kersabiec AM, Vidot F, Fontaine-Aupart MP. Copper-atom identification in the active and inactive forms of plasma-derived FVIII and recombinant FVIII-ΔII. Eur J Biochem. 1994;222(1):41–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Tagliavacca L, Moon N, Dunham WR, Kaufman RJ. Identification and functional requirement of Cu (I) and its ligands within coagulation factor VIII. J Biol Chem. 1997;272(43):27428–34.PubMedCrossRefGoogle Scholar
  13. 13.
    O’brien S, Mayewski P, Meeker L, Meese D, Twickler M, Whitlow S. Complexity of Holocene climate as reconstructed from a Greenland ice core. Science. 1995;270(5244):1962–4.CrossRefGoogle Scholar
  14. 14.
    Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 2001;86(4):959–72.PubMedGoogle Scholar
  15. 15.
    Macedo-Ribeiro S, Bode W, Huber R, Quinn-Allen MA, Kim SW, Ortel TL, et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature. 1999;402(6760):434–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Church WR, Jernigan RL, Toole J, Hewick RM, Knopf J, Knutson GJ, et al. Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins. Proc Natl Acad Sci. 1984;81(22):6934–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 Å resolution. Nature. 1999;402(6760):439–42.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    McMullen BA, Fujikawa K, Davie EW, Hedner U, Ezban M. Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A). Protein Sci. 1995;4(4):740–6.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Saenko EL, Shima M, Rajalakshmi K, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem. 1994;269(15):11601–5.PubMedGoogle Scholar
  20. 20.
    Watzka SB, Steiner M, Samorapoompichit P, Gross K, Coles JG, Wolner E, et al. Establishment of vessel-like structures in long-term three-dimensional tissue culture of myocardium: an electron microscopy study. Tissue Eng. 2004;10(11–12):1684–94.PubMedCrossRefGoogle Scholar
  21. 21.
    Faridi NJ, Kumar P, Husain N, Siddiqi MI. Factor VIII genetic mutations and protein alterations in hemophilia A: a review. Clin Rev Opin. 2014;6(1):1–10.CrossRefGoogle Scholar
  22. 22.
    Thorelli E, Kaufman RJ, Dahlbäck B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem. 1998;273(26):16140–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Swieringa F, Kuijpers MJ, Lamers MM, Van der Meijden PE, Heemskerk JW. Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow. Haematologica. 2015;100(6):748–56.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009;4(2):186–201.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. Am J Hematol. 1998;59(4):288–94.PubMedCrossRefGoogle Scholar
  26. 26.
    Manno CS. Difficult pediatric diagnoses: bruising and bleeding. Pediatr Clin N Am. 1991;38(3):637–55.CrossRefGoogle Scholar
  27. 27.
    Mauser-Bunschoten EP. Symptomatic carriers of hemophilia, vol. 46. Montreal: World Federation of Hemophilia; 2008. p. 2–3.Google Scholar
  28. 28.
    Antonarakis SE, Rossiter J, Young M, Horst J, De Moerloose P, Sommer S, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood. 1995;86(6):2206–12.PubMedGoogle Scholar
  29. 29.
    Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, van Amstel HKP, van der Bom JG, van Diemen-Homan JE, et al. Bleeding in carriers of hemophilia. Blood. 2006;108(1):52–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Khair K, Liesner R. Bruising and bleeding in infants and children–a practical approach. Br J Haematol. 2006;133(3):221–31.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Kasper CK. Hereditary plasma clotting factor disorders and their management. Haemophilia. 2000;6:13–27.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Sahu S, Lata I, Singh S, Kumar M. Revisiting hemophilia management in acute medicine. J Emerg Trauma Shock. 2011;4(2):292.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Shastry SP, Kaul R, Baroudi K, Umar D. Hemophilia A: dental considerations and management. J Int Soc Prev Community Dent. 2014;4(Suppl 3):S147.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Hardisty RM, Ingram GIC. Bleeding disorders: investigation and management. Hoboken: Blackwell Scientific Publications; 1965.Google Scholar
  35. 35.
    Holme PA, Tait RC, Combescure C, Berntorp E, Tagliaferri A, Staritz P, et al. Renal status and hematuria in older patients with hemophilia. Blood. 2015;126(23):2290.Google Scholar
  36. 36.
    Kulkarni R, Soucie JM, Evatt B. Renal disease among males with haemophilia. Haemophilia. 2003;9(6):703–10.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Sørensen B, Benson G, Bladen M, Classey S, Keeling D, McLaughlin P, et al. Management of muscle haematomas in patients with severe haemophilia in an evidence-poor world. Haemophilia. 2012;18(4):598–606.PubMedCrossRefGoogle Scholar
  38. 38.
    Balkan C, Kavakli K, Karapinar D. Iliopsoas haemorrhage in patients with haemophilia: results from one Centre. Haemophilia. 2005;11(5):463–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Jover Cerveró A, Poveda Roda R, Bagán JV, Jiménez Soriano Y. Dental treatment of patients with coagulation factor alterations: an update. Med Oral Patol Oral Cir Bucal. 2007;12(5):380–7.Google Scholar
  40. 40.
    Rodriguez-Merchan EC. Acute compartment syndrome in haemophilia. Blood Coagul Fibrinolysis. 2013;24(7):677–82.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Leslie R, Catherine M. Modern management of haemophilic arthropathy. Br J Haematol. 2007;136(6):777–87.CrossRefGoogle Scholar
  42. 42.
    Ghosh K, Ghosh K. Management of chronic synovitis in patients with hemophilia: with special reference to developing countries. Indian J Hematol Blood Transfusion. 2008;24(4):151–4.CrossRefGoogle Scholar
  43. 43.
    Nair PS, Shetty SD, Chandrakala S, Ghosh K. Mutations in intron 1 and intron 22 inversion negative haemophilia A patients from western India. PLoS One. 2014;9(5):e97337.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, et al. Structure of human factor VIII. Nature. 1984;312(5992):337–42.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Margaglione M, Castaman G, Morfini M, Rocino A, Santagostino E, Tagariello G, et al. The Italian AICE-genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica. 2008;93(5):722–8.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, et al. The human gene mutation database: 2008 update. Genome Med. 2009;1(1):13.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Salviato R, Belvini D, Radossi P, Tagariello G. Factor VIII gene intron 1 inversion: lower than expected prevalence in Italian haemophiliac severe patients. Haemophilia. 2004;10(2):194–6.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Schröder J, EL-MAARRI O, Schwaab R, Müller C, Oldenburg J, Factor VIII. Intron-1 inversion: frequency and inhibitor prevalence. J Thromb Haemost. 2006;4(5):1141–3.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Tantawy AA. Molecular genetics of hemophilia A: clinical perspectives. Egyptian J Med Human Genet. 2010;11(2):105–14.CrossRefGoogle Scholar
  50. 50.
    Chen YC, Hu SH, Cheng SN, Chao TY. Genetic analysis of haemophilia A in Taiwan. Haemophilia. 2010;16(3):538–44.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Lakich D, Kazazian HH, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet. 1993;5(3):236–41.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Levinson B, Kenwrick S, Lakich D, Hammonds G, Gitschier J. A transcribed gene in an intron of the human factor VIII gene. Genomics. 1990;7(1):1–11.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Naylor JA, Buck D, Green P, Williamson H, Bentley D, Gianneill F. Investigation of the factor VIII intron 22 repeated region (int22h) and the associated inversion junctions. Hum Mol Genet. 1995;4(7):1217–24.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Gitschier J. Molecular genetics of hemophilia A. Schweiz Med Wochenschr. 1989;119(39):1329–31.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Kemball-Cook G, Tuddenham EG. The factor VIII mutation database on the world wide web: the haemophilia a mutation, search, test and resource site HAMSTeRS update (version 3.0). Nucleic Acids Res. 1997;25(1):128–32.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost. 2003;29:23–30.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    El-Maarri O, Herbiniaux U, Graw J, Schröder J, Terzic A, Watzka M, et al. Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene. J Thromb Haemost. 2005;3(2):332–9.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Chandler WL, Ferrell C, Lee J, Tun T, Kha H. Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol. 2003;120(1):34–9.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Kitchen S, McCraw A, Echenagucia M. Diagnosis of hemophilia and other bleeding disorders. A laboratory manual. Montreal: World Federation of Hemophilia; 2000.Google Scholar
  60. 60.
    Hillarp A, Bowyer A, Ezban M, Persson P, Kitchen S. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study. Haemophilia. 2017;23(3):458–65.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Di Paola J, Smith M, Klamroth R, Mannucci P, Kollmer C, Feingold J, et al. ReFacto® and Advate®: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia. 2007;13(2):124–30.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116(2):270–9.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Peyvandi F, Oldenburg J, Friedman K. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016;14(2):248–61.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Reding M, Ng H, Poulsen LH, Eyster M, Pabinger I, Shin HJ, et al. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost. 2017;15(3):411–9.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, et al. Safety and prolonged activity of recombinant factor VIII fc fusion protein in hemophilia A patients. Blood. 2012;119(13):3031–7.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Turecek P, Bossard M, Graninger M, Gritsch H, Höllriegl W, Kaliwoda M, et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Hamostaseologie. 2012;32(1):S29–38.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Zhang Y, Limsakun T, Bensen-Kennedy DM, Veldman A, Yao Z. Population pharmacokinetic modeling and simulation of recombinant single-chain factor VIII (r VIII-SingleChain) in patients with hemophilia A. J Thromb Haemost. 2017;15(6):1106–14.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Ma AD, Roberts HR, Escobar MA. Hemophilia and hemostasis: a case-based approach to management. Hoboken: Wiley; 2012.CrossRefGoogle Scholar
  69. 69.
    O’grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011;52(9):e162-e93.Google Scholar
  70. 70.
    Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol. 2007;138(5):580–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Franchini M, Lippi G. The use of desmopressin in acquired haemophilia A: a systematic review. Blood Transfus. 2011;9(4):377.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Aledort L, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med. 1994;236(4):391–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation and management. J Comorb. 2011;1(1):51–9.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Rodriguez-Merchan E. Articular bleeding (hemarthrosis) in hemophilia. In: Schulman S, editor. An orthopedist’s point of view. 2nd ed. Montréal: The World Federation of Hemophilia; 2008. p. 1–5.Google Scholar
  75. 75.
    Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, et al. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood. 2008;112(7):2713–21.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Rea CJ, Aledort L, Rangarajan S. Haemophilia: a race for cure. Hematol Transfus Int J. 2017;4(5):00094.CrossRefGoogle Scholar
  77. 77.
    Rodriguez-Merchan E. Ankle surgery in haemophilia with special emphasis on arthroscopic debridement. Haemophilia. 2008;14(5):913–9.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Rodriguez-Merchan E. Orthopaedic surgery in persons with haemophilia. Thromb Haemost. 2003;89(1):34–42.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Pagon R, Adam M, Ardinger H, Wallace S, Amemiya A, Bean L, et al. Hemophilia A, GeneReviews®. Seattle: University of Washington; 2000.Google Scholar
  80. 80.
    Fulcher CA, de Graaf Mahoney S, Zimmerman TSFVIII. Inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood. 1987;69(5):1475–80.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost. 2004;2(7):1082–95.PubMedCrossRefGoogle Scholar
  82. 82.
    Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59–72.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Wintrobe MM. Wintrobe’s clinical hematology/clinical hematology: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009.Google Scholar
  84. 84.
    Astermark J. Overview of inhibitors. Semin Hematol. 2006;43:S3–7.PubMedCrossRefGoogle Scholar
  85. 85.
    DiMichele DM. Inhibitors in haemophilia: a primer. Haemophilia. 2000;6:38–40.PubMedCrossRefGoogle Scholar
  86. 86.
    Owaidah T, Al Momen A, Alzahrani H, Almusa A, Alkasim F, Tarawah A, et al. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: results from the Saudi national hemophilia screening program. Medicine. 2017;96(2):e5456.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Hoots W, Shapiro A. Factor VIII and factor IX inhibitors in patients with hemophilia. Waltham, MA: UpToDate; 2016.Google Scholar
  88. 88.
    Miller C, Platt S, Rice A, Kelly F, Soucie J. Validation of Nijmegen–Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012;10(6):1055–61.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Duncan E, Collecutt M, Street A. Nijmegen-Bethesda assay to measure factor VIII inhibitors. Methods Mol Biol. 2013;992:321–33.PubMedCrossRefGoogle Scholar
  90. 90.
    Guh S, Grosse S, McAlister S, Kessler C, Soucie J. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia. 2012;18(2):268–75.PubMedCrossRefGoogle Scholar
  91. 91.
    Guh S, Grosse S, McAlister S, Kessler C, Soucie J. Health care expenditures for medicaid-covered males with haemophilia in the United States, 2008. Haemophilia. 2012;18(2):276–83.PubMedCrossRefGoogle Scholar
  92. 92.
    Walsh CE, Soucie JM, Miller CH. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol. 2015;90(5):400–5.PubMedCrossRefGoogle Scholar
  93. 93.
    Orman ES, Fried MW. Hepatitis C viral infection in patients with hemophilia and hemolytic disorders. Clin Liver Dis. 2012;1(3):95–7.CrossRefGoogle Scholar
  94. 94.
    Reza Yazdani M, Kassaian N, Ataei B, Nokhodian Z, Adibi P. Hepatitis C virus infection in patients with hemophilia in Isfahan, Iran. Int J Prev Med. 2012;3(Suppl 1):S89–93.Google Scholar
  95. 95.
    Al-Kubaisy W, Al-Naib K, Habib M. Prevalence of HCV/HIV co-infection among haemophilia patients in Baghdad. East Mediterr Health J. 2006;12(3/4):264.PubMedGoogle Scholar
  96. 96.
    Berntorp E, Shapiro A, Astermark J, Blanchette V, Collins P, Dimichele D, et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia. 2006;12(s6):1–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Tjonnfjord G, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag. 2007;3(4):527.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Abildgaard CF, Penner JA, Watson-Williams EJ. Anti-inhibitor coagulant complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood. 1980;56(6):978–84.PubMedGoogle Scholar
  99. 99.
    Scully C, Dios PD, Kumar N. Special care in dentistry: handbook of oral healthcare. London: Elsevier Health Sciences; 2006.Google Scholar
  100. 100.
    Scully C, Dios PD, Giangrande P. Oral care for people with hemophilia or a hereditary bleeding tendency, Treatment of hemophilia monograph series. Montreal: The World Federation of Hemophilia; 2008. p. 10–1.Google Scholar
  101. 101.
    Wang L, Zoppè M, Hackeng TM, Griffin JH, Lee K-F, Verma IM. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci. 1997;94(21):11563–6.PubMedCrossRefGoogle Scholar
  102. 102.
    Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P, McIntosh J, Peruta MD, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen Y-M, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CYC, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994–2004.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol. 2008;140(5):479–87.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Hao Q-L, Malik P, Salazar R, Tang H, Gordon EM, Kohn DB. Expression of biologically active human factor IX in human hematopoietic cells after retroviral vector-mediated gene transduction. Hum Gene Ther. 1995;6(7):873–80.PubMedCrossRefGoogle Scholar
  105. 105.
    Swystun LL, Lillicrap D. Gene therapy for coagulation disorders. Circ Res. 2016;118(9):1443–52.PubMedCrossRefGoogle Scholar
  106. 106.
    Ponder KP. Gene therapy for hemophilia. Curr Opin Hematol. 2006;13(5):301–7.PubMedCrossRefGoogle Scholar
  107. 107.
    Chuah MK, Collen D, VandenDriessche T. Gene therapy for hemophilia: hopes and hurdles. Crit Rev Oncol Hematol. 1998;28(3):153–71.PubMedCrossRefGoogle Scholar
  108. 108.
    Morfini M. A new era in the Hemophilia treatment: lights and shadows. J Hematol Transfus. 2016;4(3):1051.Google Scholar
  109. 109.
    High KA, Anguela XM. Adeno-associated viral vectors for the treatment of hemophilia. Human Mol Genet. 2015:ddv475.Google Scholar
  110. 110.
    Finn JD, Ozelo MC, Sabatino DE, Franck HW, Merricks EP, Crudele JM, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood. 2010;116(26):5842–8.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Artenstein AW, Opal SM. Proprotein convertases in health and disease. N Engl J Med. 2011;365(26):2507–18.PubMedCrossRefGoogle Scholar
  112. 112.
    Siner JI, Samelson-Jones BJ, Crudele JM, French RA, Lee BJ, Zhou S, et al. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models. JCI Insight. 2016;1(16):e89371.Google Scholar
  113. 113.
    Powell JS, Ragni MV, White GC, Lusher JM, Hillman-Wiseman C, Moon TE, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood. 2003;102(6):2038–45.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Miao CH. Hemophilia A: gene therapy via intraosseous delivery of factor VIII-lentiviral vectors. Thromb J. 2016;14(1):41–e89371.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    James PD, Raut S, Rivard GE, Poon M-C, Warner M, McKenna S, et al. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood. 2005;106(9):3043–8.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Chao H, Mansfield SG, Bartel RC, Hiriyanna S, Mitchell LG, Garcia-Blanco MA, et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med. 2003;9(8):1015–9.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Zhang F, Wen Y, Guo X. CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet. 2014;23(R1):R40–6.PubMedCrossRefGoogle Scholar
  118. 118.
    Nguyen TH, Anegon I. Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo: delivery vector and immune responses are the key to success. EMBO Mol Med. 2016;8(5):439–41.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Mohammad Saeed Gholami
    • 2
    • 1
  • Mohsen Valikhani
    • 2
  • Akbar Dorgalaleh
    • 2
  • Sayed Hamid Mousavi
    • 3
    • 4
  • Behnaz Pezeshkpoor
    • 5
    Email author
  1. 1.Student Research CommitteeSchool of Allied Medicine, Iran University of Medical SciencesTehranIran
  2. 2.Department of Hematology and Blood TransfusionSchool of Allied Medicine, Iran University of Medical SciencesTehranIran
  3. 3.Department of the Clinical BiochemistryFaculty of Medical Sciences, Kateb UniversityKabulAfghanistan
  4. 4.Afghanistan National Charity Organization for Special Diseases (ANCOSD)KabulAfghanistan
  5. 5.Institute of Experimental Hematology and Transfusion Medicine, University of BonnBonnGermany

Personalised recommendations